Proceeds are earmarked to fund the registrational Phase 3 ROBBIN neoadjuvant BOT+BAL trial in MSS colon cancer, extending runway through year-end 2031 if fully exercised.
The board is set to expand to nine members, with two Class III seats designated by Commodore Capital.
Private placement terms and potential proceeds
Agenus priced an oversubscribed private placement targeting USD 85 million in upfront gross proceeds, with up to USD 255 million more from warrant exercises.
The deal includes 23,035,227 common shares or pre-funded warrants, with Series A warrants for 21,144,277 shares at USD 4.02.
It also issued Series B warrants for 33,797,214 shares at USD 5.03; combined gross proceeds could reach USD 340 million.
AGEN•
